6120-95-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenyl-1-cyclopropanecarboxylic acid is used as an intermediate in the synthesis of pharmaceutical products for its ability to be incorporated into the molecular structures of various inhibitors and anticancer compounds. This allows for the development of new and effective treatments for a range of diseases and conditions.
Used in Synthesis of 2-(1-Phenylcyclopropyl)-4-oxazolecarboxylic Acid (P319785):
1-Phenyl-1-cyclopropanecarboxylic acid is used as the starting material in the synthesis of 2-(1-Phenylcyclopropyl)-4-oxazolecarboxylic Acid (P319785), a compound with potential applications in the pharmaceutical industry. This synthesis process highlights the versatility and importance of 1-Phenyl-1-cyclopropanecarboxylic acid as a building block in the creation of new and innovative pharmaceutical agents.

InChI:InChI=1/C10H10O2/c11-9(12)10(6-7-10)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,11,12)/p-1

Upstream product

• 935-44-4 1-cyano-1-phenylcyclopropane 
• 6120-96-3 1-phenyl-1-cyclopropanecarboxamide 
• 87328-17-4 ethyl 1-phenyl-1-cyclopropanecarboxylate 
• 1007-71-2 1-(1-phenyl-cyclopropyl)-ethanone 
• 31729-66-5 1-phenyl-1-cyclopropanemethanol 
• 103-82-2 phenylacetic acid 
• 106-93-4 ethylene dibromide 
• 140-29-4 phenylacetonitrile 
• 65655-78-9 ethyl 2,2-dibromo-1-phenylcyclopropanecarboxylate 
• 22286-82-4 2-phenyl-acrylic acid ethyl ester 
• 52370-86-2 ethyl 4-chloro-2-cyano-2-phenylbutanoate 
• 4553-07-5 ethyl phenylcyanoacetate 
• 103-79-7 1-phenyl-acetone 
• 101-41-7 benzeneacetic acid methyl ester 

Downstream Products

• 87328-17-4 ethyl 1-phenyl-1-cyclopropanecarboxylate 
• 873-49-4 cyclopropylbenzene 
• 1308814-98-3 ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate 
• 63201-02-5 1-phenylcyclopropanecarbonyl chloride 
• 31729-66-5 1-phenyl-1-cyclopropanemethanol 
• 1007-71-2 1-(1-phenyl-cyclopropyl)-ethanone 
• 130553-66-1 1-Phenyl-cyclopropanecarboxylic acid methyl-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-amide 
• 637-50-3 1-phenylpropene 
• 77197-87-6 1-phenyl-1-bromocyclopropane 
• 82203-34-7 bis<(1-phenyl-1-cyclopropyl)carbonyl>peroxide 
• 3127-67-1 2-phenyl-but-2-enoic acid 
• 116005-40-4 1-phenylchlorocyclopropane 
• 86101-65-7 1-(cyclopropylcarbonyl)cyclopropanecarboxylic acid 
• 56771-48-3 1-Methylamino-1-phenyl-cyclopropan 

Relevant academic research and scientific papers

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Free Carboxylic Acids

A monoprotected aminoethyl amine chiral ligand based on an ethylenediamine backbone was developed to achieve Pd-catalyzed enantioselective C(sp3)-H arylation of cyclopropanecarboxylic and 2-aminoisobutyric acids without using exogenous directing groups. This new chiral catalyst affords new disconnection for preparing diverse chiral carboxylic acids from simple starting materials that are complementary to the various ring forming approaches.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

Pyruvate kinase activators for use in therapy

Described herein are methods for using compounds that activate pyruvate kinase.

PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are useful as HIV attachment inhibitors.

KAPPA OPIOID RECEPTOR AGONISTS

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, Rls R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

Imidazolium salts as phase transfer catalysts for the dialkylation and cycloalkylation of active methylene compounds

The efficient synthesis of 1,1-disubstituted derivatives and the construction of cyclopropane and cyclopentane ring systems via dialkylation and cycloalkylation reactions of active methylene compounds using imidazolium salts as phase transfer catalyst is described. The dialkylation and cycloalkylation reactions of active methylene compounds in the presence of readily available imidazolium salts (ionic liquids) as phase transfer catalysts were performed to afford the respective dialkylated or cycloalkylated products. This method is very efficient for the synthesis of 1,1-disubstituted derivatives and cyclopropane and cyclopentane ring systems in a facile manner.